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Abstract
Objective. To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference
etanercept (ETN) in patients with active RA.
Methods. In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA
despite MTX treatment were randomized to receive 50 mg/week of s.c. SB4 or ETN up to week 52.
Efficacy assessments included ACR response rates, 28-joint DAS, Simplified and Clinical Disease
Activity Indices and changes in the modified total Sharp score (mTSS). Safety and immunogenicity
were also evaluated.
Results. A total of 596 patients were randomized to receive either SB4 (n= 299) or ETN (n= 297) and 505
(84.7%) patients completed 52 weeks of the study. At week 52, the ACR20 response rates in the per-
protocol set were comparable between SB4 (80.8%) and ETN (81.5%). All efficacy results were compar-
able between the two groups and they were maintained up to week 52. Radiographic progression was
also comparable and the change from baseline in the mTSS was 0.45 for SB4 and 0.74 for ETN. The
safety profile of SB4 was similar to that of ETN and the incidence of anti-drug antibody development up to
week 52 was 1.0 and 13.2% in the SB4 and ETN groups, respectively.
Conclusion. Efficacy including radiographic progression was comparable between SB4 and ETN up to
week 52. SB4 was well tolerated and had a similar safety profile to that of ETN.
Trial registration number: ClinicalTrials.gov NCT01895309, EudraCT 2012-005026-30
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Rheumatology key messages
. The efficacy of SB4 and reference etanercept was comparable and maintained up to week 52.
. Radiographic progression was comparable between SB4 and reference etanercept.
. SB4 was well tolerated and had a similar safety profile to reference etanercept.
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Introduction
Targeted biologic therapies such as TNF inhibitors have
revolutionized the treatment of RA, AS, psoriasis and
other immune-mediated inflammatory diseases [1].
However, the high cost of these treatments places a sub-
stantial financial burden on patients and health care sys-
tems [2, 3]. Along with the economic burden and imminent
patent expiration on many biologic therapies, the interest
in biosimilars has increased. In an analysis that assessed
the budget impact of introducing an etanercept biosimilar
to the five largest European countries for treatment of all
licensed reference etanercept (ETN) indications for adults,
the substantial cost savings could potentially be used to
treat an additional 3100 (UK) to 17 130 (Germany) patients
over 5 years, based on a 10 or 25% cost reduction com-
pared with ETN [4].
SB4 is a biosimilar to ETN. Equivalence in pharmaco-
kinetics between SB4 and ETN was demonstrated in a
phase 1 study conducted in healthy male subjects [5]
and equivalent efficacy and comparable safety between
SB4 and ETN up to 24 weeks were demonstrated in a
phase 3 study conducted in patients with RA [6].
This report provides data up to 52 weeks from the phase
3 study.
Methods
Patients
Patient eligibility criteria have been described in detail pre-
viously [6]. Briefly, patients diagnosed with RA for
56 months and415 years prior to screening, with a swol-
len joint count (SJC)56 and a tender joint count (TJC)56
and either ESR528 mm/h or serum CRP51.0 mg/dl and
patients who took MTX for 56 months (stable dose of
1025 mg/week for54 weeks prior to screening) were eli-
gible for the study.
Study design
Eligible patients were randomized in a 1:1 ratio to receive
50 mg/week of either SB4 or ETN for up to 52 weeks via
self-administered s.c. injection with background MTX
(1025 mg/week) and folic acid (510 mg/week). The
study was conducted between June 2013 and
November 2014 at 73 centres across 10 countries in
Europe, Latin America and Asia.
This study was conducted in compliance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines established by the International Conference
Harmonisation. The protocol was reviewed and approved
by the institutional review board or the independent ethics
committee of each investigational centre. All patients pro-
vided written informed consent prior to any study-related
procedures.
Assessments
The primary endpoint of this study was the proportion of
patients achieving at least 20% improvement in the ACR
response criteria (ACR20) at week 24 (results reported
previously [6]). Efficacy endpoints up to week 52 included
the ACR20, 50 and 70 responses, the numeric index of the
ACR response (ACR-N), change in the 28-joint DAS
(DAS28) based on ESR and the EULAR response. Major
clinical response (ACR70 response for six consecutive
months) was assessed at week 52.
Simplified Disease Activity Index (SDAI) and Clinical
Disease Activity Index (CDAI) scores, the proportion of
patients achieving Boolean-based remission [defined as
an SJC 41 and a TJC 41, CRP 41 mg/dl and patient
global visual analogue scale (VAS)41 using a 010 scale]
and remission based on different indices (DAS28 <2.6,
SDAI 43.3, CDAI 42.8) were assessed through post
hoc analyses. Physical function and disability were as-
sessed through the HAQ Disability Index (HAQ-DI).
Radiographs of the hands and feet were obtained at
baseline and week 52. The images were evaluated by
two independent readers who were blinded to patient
identity, treatment and the time point taken. When the
change score was within the top 5% of cases with the
highest differences in score between readers, the radio-
graphs required consensus review by the primary readers.
The mean joint erosion and joint space narrowing score of
the two readers were used to calculate the van der Heijde
modification of the total Sharp score (mTSS) [7]. The pro-
portion of patients with a change in mTSS >0 and mTSS
greater than the smallest detectable change (SDC) was
calculated post hoc.
Safety assessments included the incidence of adverse
events (AEs) and serious AEs (SAEs). Anti-drug antibodies
(ADAs) and neutralizing antibodies were measured at weeks
0, 2, 4, 8, 12, 16, 24 and 52. A single-assay approach with
SB4 tag was used to assess immunogenicity. ADAs were
measured using validated electrochemiluminesence im-
munoassays and neutralizing antibodies were measured
using a competitive ligand-binding assay [MesoScale
Discovery (MSD) platform, MesoScale Discovery,
Rockville, MD, USA).
Statistical analyses
ACR responses at week 52 were analyzed on the per-
protocol set (PPS) in which patients completed the week
52 visit and received 80120% of both the expected
number of study drug administrations and the expected
sum of MTX doses without any major protocol deviations
affecting the efficacy assessment. The 95% CI of the ad-
justed treatment difference of ACR responses was esti-
mated using the non-parametric analysis of covariance
(ANCOVA) method including baseline CRP as a covariate
and the MantelHaenszel weight for region. To explore the
robustness of the results, the same analysis was repeated
for the full analysis set (FAS; all patients who were rando-
mized and received at least one dose of study drug fol-
lowing the intent-to-treat principle) with non-responder
imputation for missing data. Other efficacy endpoints at
week 52 were summarized descriptively in the FAS with-
out any imputation for missing data.
The radiographic progression between treatment
groups was compared with an ANCOVA model for the
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change in mTSS with treatment group and region as fac-
tors and the baseline mTSS as a covariate. In addition, the
association of patients with change in mTSS based on
SDC (<2.3 vs 52.3) and treatment was analysed post
hoc using the chi-square test and the proportion of the
progressed patients with a change in mTSS >0 was also
compared on the FAS. Safety and immunogenicity end-
points were analysed descriptively on the safety set in
which all patients received at least one study drug admin-
istration. All statistical analyses were performed using
SAS software version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patient disposition and baseline characteristics
Patient screening started in June 2013 and the 52 week
evaluation of the last patient was performed in November
2014. Overall, 596 patients were randomized to receive
SB4 (n= 299) or ETN (n= 297) and 505 (84.7%) patients
completed 52 weeks of treatment (Fig. 1). The PPS for the
52 week analysis consisted of 224 patients from the SB4
group and 216 patients from the ETN group. Baseline
demographic and disease characteristics were compar-
able between treatment groups (Table 1).
Clinical efficacy
The ACR responses of SB4 were comparable with those
of ETN over the time course of the study (Fig. 2). The
ACR20 response rate at week 52 in the PPS was 80.8%
for SB4 and 81.5% for ETN and the 95% CI of the ad-
justed difference (SB4ETN) was 8.036.56%. The
ACR50 and ACR70 responses at week 52 in the PPS
were 58.5 vs 53.2% and 37.5 vs 31.0% in the SB4 and
the ETN groups, respectively. Similar results were shown
in the FAS with non-responder imputation with all ACR
responses. The results for both PPS and FAS non-re-
sponder imputation together with the 95% CIs can be
found in supplementary Table S1, available at
Rheumatology Online. Subgroup analysis on the ACR20
response rates at week 52 in PPS showed comparable
results between the SB4 and ETN group when analysed
by the presence of ADA (see supplementary Table S2,
available at Rheumatology Online).
Maintenance of response from week 24 to week 52 was
observed (Table 2). Among patients who achieved ACR
responses at week 24, a similar proportion of patients in
the SB4 and ETN groups maintained the level of re-
sponses at week 52 (90% for ACR20, 80% for ACR50
and 80% for ACR70). Of the patients who were not ACR
responders at week 24, a similar proportion of patients in
the SB4 and ETN groups subsequently achieved ACR re-
sponses at week 52 (46.6 vs 41.3% for ACR20, 31.9 vs
28.3% for ACR50 and 21.5 vs 15.2% for ACR70,
respectively).
Other efficacy results at week 52 are presented in
Table 2. The mean improvement from baseline in DAS28
was 2.91 for SB4 and 2.80 for ETN and the 95% CI of the
difference (SB4ETN) in the improvement in DAS28 was
0.0920.328. Likewise, at week 52 the mean improve-
ment from baseline in SDAI and CDAI were comparable
between SB4 and ETN (28.7 vs 27.7 and 27.9 vs 26.8,
respectively). The proportion of patients achieving good
or moderate EULAR response for SB4 and ETN was 92.7
and 91.1%, respectively. Assessment of patient-reported
physical function measured by the HAQ-DI at week 52
showed similar improvements between the two treatment
groups. The mean improvement was 0.73 in SB4 and 0.70
in ETN.
FIG. 1 Summary of patient disposition
Among the patients who withdrew under investigator discretion, 13 patients in the SB4 group and 8 patients in the ETN
group were withdrawn due to the political crisis in Ukraine. ETN: reference etanercept.
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In addition, the proportion of patients achieving remis-
sion was comparable between the two treatment groups
(Table 2). In the SB4 and ETN groups, 15.4 vs 13.5% pa-
tients reached Boolean-based remission and 26.5 vs
19.1%, 23.8 vs 20.4% and 21.9 vs 19.5% patients
achieved remission by DAS28, SDAI and CDAI, respect-
ively. All efficacy results were comparable throughout the
study and a graphical presentation of the mean DAS28,
CDAI, SDAI and HAQ-DI scores is shown in supplemen-
tary Figs. S1S4, available at Rheumatology Online.
Radiographic progression
The radiographic progression from baseline up to week 52
was comparable between the two treatment groups (SB4,
n= 250; ETN, n= 228) (Table 2 and Fig. 3). The mean
change from baseline in mTSS was 0.45 and 0.74 in the
SB4 and ETN groups, respectively, and the 95% CI of the
difference in mTSS was0.80 to 0.26. Overall 30.0% of
patients in SB4 and 34.2% of patients in ETN had a
change from baseline in mTSS of >0 (P = 0.325). When
evaluated by progression based on the SDC (2.3), 8.4
TABLE 1 Baseline demographics and disease characteristics
Characteristics SB4 50 mg (n = 299) ETN 50 mg (n = 297) Total (n = 596)
Age, years 52.1 (11.72) 51.6 (11.63) 51.8 (11.67)
Age group, n (%)
<65 years 253 (84.6) 262 (88.2) 515 (86.4)
565 years 46 (15.4) 35 (11.8) 81 (13.6)
Gender, n (%)
Male 50 (16.7) 44 (14.8) 94 (15.8)
Female 249 (83.3) 253 (85.2) 502 (84.2)
Race, n (%)
White 279 (93.3) 273 (91.9) 552 (92.6)
American Indian or Alaskan Native 5 (1.7) 7 (2.4) 12 (2.0)
Asian 11 (3.7) 13 (4.4) 24 (4.0)
Other 4 (1.3) 4 (1.3) 8 (1.3)
Weight, kg 72.5 (15.93) 71.0 (14.63) 71.8 (15.30)
Height, cm 164.4 (8.78) 164.4 (8.55) 164.4 (8.66)
BMI, kg/m2 26.8 (5.51) 26.3 (5.30) 26.6 (5.41)
Disease duration, years 6.0 (4.20) 6.2 (4.41) 6.1 (4.30)
Duration of MTX use, months 48.2 (39.89) 47.1 (40.73) 47.7 (40.28)
MTX dose, mg/week 15.6 (4.52) 15.5 (4.60) 15.5 (4.56)
CRP, mg/dl 1.5 (2.00) 1.3 (1.60) 1.4 (1.81)
ESR, mm/h 46.5 (22.10) 46.4 (22.62) 46.5 (22.34)
RF positive, n (%) 237 (79.3) 231 (77.8) 468 (78.5)
Swollen joint count (066) 15.4 (7.48) 15.0 (7.30) 15.2 (7.39)
Tender joint count (068) 23.5 (11.90) 23.6 (12.64) 23.5 (12.26)
HAQ-DI (03) 1.49 (0.553) 1.51 (0.560) 1.50 (0.556)
Physician global assessment VAS (0100) 62.2 (15.09) 63.2 (14.76) 62.7 (14.92)
Patient global assessment VAS (0100) 61.7 (18.97) 63.0 (17.70) 62.4 (18.35)
Patient pain assessment VAS (0100) 61.8 (20.22) 62.3 (19.22) 62.1 (19.71)
DAS28-ESR 6.48 (0.906) 6.46 (0.885) 6.47 (0.895)
Simplified disease activity index 39.8 (12.76) 39.4 (11.81) 39.6 (12.29)
Clinical disease activity index 38.4 (12.24) 38.1 (11.57) 38.2 (11.90)
Joint space narrowing scorea 19.2 (28.83) 18.4 (26.48) 18.8 (27.71)
Joint erosion scorea 24.0 (39.63) 20.5 (28.32) 22.4 (34.71)
Modified total Sharp scorea 43.3 (67.08) 38.9 (53.26) 41.2 (60.86)
Values are mean (S.D.) unless indicated otherwise. aBased on patients with available radiographic data. ETN: reference
etanercept; VAS: visual analogue scale.
FIG. 2 ACR response rates up to week 52 (full
analysis set)
ETN: reference etanercept.
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and 14.0% of patients in the SB4 and the ETN groups,
respectively, showed radiographic progression.
Safety
Overall, 175 (58.5%) patients in the SB4 group and 179
(60.3%) patients in the ETN group reported at least one
treatment-emergent adverse event (TEAE) during the
study up to week 52. Frequently occurring TEAEs by pre-
ferred term are shown in Table 3. The most frequently
reported TEAEs were upper respiratory tract infection
(8.0%) and an increase in alanine aminotransferase (ALT;
6.0%) in the SB4 group and injection site erythema
(11.1%) and an increase in ALT (5.7%) in the ETN
group. Most of the TEAEs were mild to moderate in se-
verity and TEAEs considered related to the study drug
were reported in 88 (29.4%) and 109 (36.7%) patients
for SB4 and ETN, respectively. Serious TEAEs were re-
ported in 18 (6.0%) patients in the SB4 group and 15
(5.1%) patients in the ETN group and 36 patients discon-
tinued treatment due to TEAEs [16 (5.4%) vs 20 (6.7%)
patients in the SB4 and ETN groups, respectively].
Patients who had a history of tuberculosis (TB) or who
were considered to have latent TB through the
QuantiFERON Gold test at the time of screening were
included in the study if they completed at least 30 days
of treatment for latent TB prior to the first study drug ad-
ministration. At screening, 12 patients from the SB4 group
TABLE 2 Efficacy results at week 52 in FAS with no imputation
Result SB4 50 mg (n = 299) ETN 50 mg (n = 297)
ACR response
ACR20 210/259 (81.1) 195/246 (79.3)
Maintenance of response among week 24 responders 183/201 (91.0) 176/200 (88.0)
Response among week 24 non-responders 27/58 (46.6) 19/46 (41.3)
ACR50 143/259 (55.2) 125/246 (50.8)
Maintenance of response among week 24 responders 98/118 (83.1) 86/108 (79.6)
Response among week 24 non-responders 45/141 (31.9) 39/138 (28.3)
ACR70 91/259 (35.1) 73/246 (29.7)
Maintenance of response among week 24 responders 49/64 (76.6) 44/55 (80.0)
Response among week 24 non-responders 42/195 (21.5) 29/191 (15.2)
ACR-N, mean (S.D.) 52.08 (30.277) 49.17 (30.299)
Major clinical responsea 54/259 (20.8) 45/246 (18.3)
DAS28-ESR
Improvement from baseline, mean (S.D.) 2.91 (1.360) 2.80 (1.288)
Disease activity
Low (43.2) 109/260 (41.9) 86/246 (35.0)
Remission (<2.6) 69/260 (26.5) 47/246 (19.1)
EULAR response
Good 108/259 (41.7) 85/246 (34.6)
Moderate 132/259 (51.0) 139/246 (56.5)
No response 19/259 (7.3) 22/246 (8.9)
HAQ-DI
Improvement from baseline, mean (S.D.) 0.73 (0.582) 0.70 (0.623)
SDAI score
Improvement from baseline, mean (S.D.) 28.7 (13.32) 27.69 (13.740)
Disease activity
Low (>3.3 and 411) 93/260 (35.8) 92/245 (37.6)
Remission (43.3) 62/260 (23.8) 50/245 (20.4)
CDAI score
Improvement from baseline, mean (S.D.) 27.9 (12.94) 26.8 (13.56)
Disease activity
Low (>2.8 and 410) 94/260 (36.2) 82/246 (33.3)
Remission (42.8) 57/260 (21.9) 48/246 (19.5)
Boolean-based remissionb 40/260 (15.4) 33/245 (13.5)
Radiographic resultsc
Change from baseline in JSN score, mean (S.D.) 0.18 (1.142) 0.43 (2.096)
Change from baseline in joint erosion score, mean (S.D.) 0.26 (1.608) 0.31 (1.677)
Change from baseline in mTSS, mean (S.D.) 0.45 (2.497) 0.74 (3.356)
Patients with change from baseline in mTSS > 0 75/250 (30.0) 78/228 (34.2)
Patients with progression based on the SDCd 21/250 (8.4) 32/228 (14.0)
Values are the number of patients/total number (%) unless indicated otherwise. aACR70 response for 6 consecutive months.
bDefined as SJC 41, TJC 41, CRP 41 mg/dl and patient global VAS 41 using a 010 scale. cBased on patients with
available radiographic results at weeks 0 and 52 (SB4, n= 250; ETN, n= 228). dSDC = 2.3 for change in mTSS. ETN: reference
etanercept; JSN: joint space narrowing.
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and 15 patients from the ETN group were considered to
have latent TB and no cases of active TB were reported
during the study. Serious infections were reported in one
(0.3%) patient in the SB4 group (cholecystitis, peritonitis
and liver abscess) and five (1.7%) patients in the ETN
group (pneumonia, two patients with cellulitis, appendi-
citis and erysipelas). Malignancies were reported in four
(1.3%) patients in the SB4 group (gastric adenocarcin-
oma, basal cell carcinoma, breast cancer and lung
cancer metastatic) and in one (0.3%) patient in the ETN
group (invasive ductal breast carcinoma). Breast cancer in
the SB4 group and invasive ductal breast carcinoma in the
ETN group were considered by the investigator to be
related to the study drug, but the other three malignancies
were not considered to be related to the study drug.
Injection site reactions (ISRs), counted by the high-level
group term of administration site reaction, occurred in sig-
nificantly fewer patients in the SB4 group compared with
the ETN group. One additional patient treated with ETN
reported ISRs after the data cut-off point for the 24-week
report and the overall incidence of ISRs up to week 52
was 3.7% (22 ISRs reported in 11 patients) in the SB4
group and 17.5% (157 ISRs reported in 52 patients) in
the ETN group (P< 0.001). The ISRs reported by preferred
term can be found in supplementary Table S3, available at
Rheumatology Online. ISRs were also counted as a sep-
arate assessment by the investigator at every visit.
The evaluation was reported as an ISR when the evalu-
ation result indicated clinically significant abnormality or
the abnormality of the ISRs worsened after study drug
administration compared with the previous ISR. The inci-
dence of ISR reported in this manner (up to week 52) was
lower in the SB4 group than the ETN group [2 (0.7%) vs 17
(5.7%) patients]. Two deaths were reported in the SB4
treatment group due to cardiopulmonary failure and gas-
tric adenocarcinoma and both were reported to be not
related to the study drug.
Immunogenicity
The incidence of ADAs was significantly lower in the SB4
group compared with the ETN group up to week 52. After
week 24, only one patient from the SB4 group developed
TABLE 3 TEAEs reported in52% of patients by preferred term
Preferred term SB4 50 mg (n = 299) ETN 50 mg (n = 297)
Upper respiratory tract infection 24 (8.0) 16 (5.4)
Alanine aminotransferase increased 18 (6.0) 17 (5.7)
Nasopharyngitis 15 (5.0) 16 (5.4)
Headache 13 (4.3) 8 (2.7)
Hypertension 11 (3.7) 11 (3.7)
Rheumatoid arthritis 9 (3.0) 10 (3.4)
Aspartate aminotransferase increased 8 (2.7) 9 (3.0)
Viral infection 7 (2.3) 5 (1.7)
Injection site erythema 6 (2.0) 33 (11.1)
Bronchitis 6 (2.0) 6 (2.0)
Rash 6 (2.0) 4 (1.3)
Rhinitis 6 (2.0) 4 (1.3)
Leucopenia 6 (2.0) 3 (1.0)
Pharyngitis 5 (1.7) 8 (2.7)
Diarrhoea 5 (1.7) 7 (2.4)
Urinary tract infection 5 (1.7) 7 (2.4)
Cough 4 (1.3) 10 (3.4)
Lymphocyte count decreased 4 (1.3) 6 (2.0)
Erythema 2 (0.7) 10 (3.4)
Dizziness 2 (0.7) 7 (2.4)
Injection site rash 2 (0.7) 6 (2.0)
Injection site reaction 1 (0.3) 8 (2.7)
Values are n (%).
FIG. 3 Change in mTSS at week 52
ETN: reference etanercept.
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ADA and the overall incidence of ADAs up to week 52 was
1.0 (3/299) vs 13.2% (39/296) in the SB4 and ETN groups
(P< 0.001), respectively. Among the patients who de-
veloped ADAs, only one patient with an antibody titre of
1024 from the ETN group had ADAs with neutralizing cap-
acity. Almost all ADAs were transient and all patients were
reported as positive only once throughout the study
except for one patient in the ETN group. This patient
tested positive for ADA at two visits (weeks 4 and 8).
The median peak antibody titre was 4 in the SB4 group
(range 232) and 16 in the ETN group (range 21024).
Discussion
In this randomized, double-blind, parallel-group, multicen-
tre study, 1 year efficacy, safety and immunogenicity of
SB4 were compared with those of ETN in patients with
moderate to severe RA despite MTX treatment. The
24 week results, including the primary efficacy endpoint
(ACR20 response at week 24) have been reported previ-
ously and demonstrated equivalent clinical efficacy and
comparable safety between SB4 and ETN. This report
shows that the comparable improvement in efficacy as
well as the similar safety profile is sustained between
SB4 and ETN up to week 52. In addition, this report in-
cludes radiographic results of a biosimilar and demon-
strated that treatment with a biosimilar not only
improves clinical and functional outcomes, but also re-
duces the rate of radiographic progression to a compar-
able extent to the reference product.
Of the 596 randomized patients, 505 (84.7%) patients
completed 52 weeks of treatment. When excluding pa-
tients in Ukraine who withdrew from the study due to
the political crisis (Fig. 1), the overall retention rate was
90.6% in the SB4 group and 85.1% in the ETN group. The
retention rate is higher compared with what has been re-
ported in previous studies or in daily practice with TNF
inhibitor biologics [811], implying that SB4 and ETN
were well tolerated in this study. Additionally, patients
were partly recruited from regions where access to tar-
geted biologic therapies is limited other than through par-
ticipation in clinical studies and access to etanercept in
this study may have contributed to the higher retention
rate.
As the adjusted treatment difference in ACR20 re-
sponse rate was within the predefined equivalence
margin, therapeutic equivalence between SB4 and ETN
was demonstrated. At week 52, ACR20, ACR50 and
ACR70 response rates; ACR-N; DAS28 and EULAR re-
sponse rates were similar between SB4 and ETN, indicat-
ing comparable long-term efficacy between SB4 and ETN.
Approximately 8090% of the ACR20, ACR50 and
ACR70 responders at week 24 in the SB4 and ETN
groups sustained their responses up to week 52. Among
patients who did not achieve ACR responses at week 24,
a substantial proportion (2040%) of patients achieved
ACR responses at week 52, which is a similar result to
the retrospective analysis from the TEMPO study between
weeks 12 and 24 [12]. Furthermore, in a study where pa-
tients who responded inadequately to anti-TNF therapy
and switched to abatacept as a second-line biologic,
50.4, 20.3 and 10.2% of patients achieved ACR20,
ACR50 and ACR70 responses, respectively, after
6 months of treatment [13]. Similarly, 35, 16 and 10% of
patients treated with golimumab [14] and 50.0, 28.8 and
12.4% of patients treated with tocilizumab [15] achieved
ACR20, ACR50 and ACR70 responses, respectively, after
24 weeks of treatment. Although it is recommended to
adjust the treatment when there is no improvement by
3 months, or at most when the target has not been
reached by 6 months [16], the above results suggest that
maintaining the original treatment could improve clinical
response to a similar extent as switching to second-line
biologics.
In addition to ACR response rates, various other effi-
cacy responses and self-reported outcomes were ana-
lysed not only at specific time points but at every visit
during the study. The efficacy endpoints including ACR-
N, DAS28, EULAR responses and HAQ-DI were similar
over the time course of the study. Demonstration of similar
kinetics of the clinical responses in various efficacy end-
points throughout the study provides additional evidence
on the biosimilarity of SB4 to ETN [17].
The importance of radiographic inhibition in the evalu-
ation of treatment efficacy has been noted previously
[18]. Although radiographic changes cannot be used to de-
termine therapeutic equivalence due to the low power from
small differences in radiographic outcomes, it is an object-
ive indicator to compare disease progression. Here we
report the results on structural damage assessed on plain
films. In both the SB4 and ETN groups, the radiographic
progression measured by the change in mTSS was minimal
and the numerical values were consistent with previous
reports (0.45 in SB4 and 0.74 in ETN) [19]. To further com-
pare the structural damage between the two groups, the
proportion of patients showing radiographic progression
beyond the SDC (SDC = 2.3 in this study, 8.4% for SB4
and 14.0% for ETN; P= 0.050) and the proportion of pa-
tients with mTSS >0 (0.0% for SB4 and 34.2% for ETN;
P= 0.325) was assessed. These results suggest that the
overall radiographic progression was numerically similar,
although the study was not powered to show a difference.
Overall, the safety profile of SB4 up to week 52 was com-
parable to that of ETN and was similar to those observed in
the pivotal trials with ETN.
No cases of active TB were reported during the study
and only one patient (0.3%) in the SB4 and five patients
(1.7%) in the ETN group reported serious infections. The
incidence of serious infections observed in the ETN group
in this study is lower than that in certain pivotal trials or
long-term, open-label extension trials with ETN [10, 11,
20, 21] and similar to that in two pivotal trials with ETN
[22, 23].
Malignancies were reported in four (1.3%) patients from
the SB4 group and one (0.3%) patient from the ETN
group. The incidence of malignancy observed in this
study is similar to previously conducted studies [1925].
No cases of lymphoproliferative disease or lymphoma
were reported.
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The cumulative percentage of patients with ISRs up to
week 52 was 3.7 and 17.5% in the SB4 and ETN groups,
respectively. The most common symptom of ISR was red-
ness. Two patients in the SB4 group and seven patients in
the ETN group were withdrawn from the study due to AEs
of ISRs.
In line with earlier findings on ADAs against ETN, most
of the ADAs in this study were transient and detected in
the early phase of the treatment (week 4) [6]. There was
only one additional patient from the SB4 treatment group
who developed ADA after week 24. The overall ADA inci-
dence up to week 52 was 1.0% in the SB4 group and
13.2% in the ETN group. The immunogenicity result was
lower in the SB4 group compared with the ETN group
when it was reassessed in the pharmacokinetics popula-
tion with an advanced assay in terms of drug tolerance
[26]; additional information on the immunogenicity assess-
ment and results of this study has been published in the
correspondences by Emery et al. [2729]. Despite the dif-
ference in immunogenicity profile, there was no impact on
clinical efficacy or safety. The ACR20, 50 and 70 response
rates at week 52 among patients without ADA were com-
parable between the SB4 and ETN groups (see supple-
mentary Table S2, available at Rheumatology Online).
The safety and efficacy of SB4 up to week 100 was
further assessed in an open-label extension study in a
subset of patients who completed the 52 week
randomized controlled period of the study [30].
In conclusion, SB4 has shown comparable clinical effi-
cacy, including radiographic progression, to ETN and
maintenance of efficacy up to week 52. SB4 was well
tolerated with a similar 1 year safety profile to ETN.
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